Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 13;6(3):MMT28.
doi: 10.2217/mmt-2019-0009.

An update on adjuvant systemic therapies in melanoma

Evangeline Samuel  1 , Maggie Moore  2 , Mark Voskoboynik  2 , Mark Shackleton  2 , Andrew Haydon  2
Affiliations
Review

An update on adjuvant systemic therapies in melanoma

Evangeline Samuel et al. Melanoma Manag. .

Abstract

There is a global increase in the incidence of melanoma, with approximately 300,000 new cases in 2018 worldwide, according to statistics from the International Agency for Research on Cancer. With this rising incidence, it is important to optimize treatment strategies in all stages of the disease to provide better patient outcomes. The role of adjuvant therapy in patients with resected stage 3 melanoma is a rapidly evolving field. Interferon was the first agent shown to have any utility in this space, however, recent advances in both targeted therapies and immunotherapies have led to a number of practice changing adjuvant trials in resected stage 3 disease.

Keywords: AJCC; adjuvant treatment; immunotherapy; interferon; ipilimumab; stage 3 melanoma; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Kaplan–Meier estimate of recurrence-free survival in the overall intention-to-treat population in those who received pembrolizumab compared with placebo.
Figure 2.
Figure 2.. Kaplan–Meier estimates of relapse-free survival among the patients who received combination therapy with dabrafenib plus trametinib and those who received placebo in the intention-to-treat analysis.
See this image and copyright information in PMC

References

    1. Balch CM, Gershenwald JE, Soong SJ. et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J. Clin. Oncol. 28(14), 2452–2459 (2009). - PMC - PubMed
    1. Castello G, Ruocco V, Satriano RA, Zarrilli D. Role of interferons in the therapy of melanoma. Melanoma Res. 1(5–6), 311–325 (1992). - PubMed
    1. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1), 7–17 (1996). - PubMed
    1. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10(5), 1670–1677 (2004). - PubMed
    1. Eggermont AM, Suciu S, Testori A. et al. Long-term results of the randomized Phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J. Clin. Oncol. 30(31), 3810–3818 (2012). - PubMed

LinkOut - more resources